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Abstract 
Perivascular adipose tissue (PVAT) plays a critical role in the pathogenesis of cardiovascular 
disease. In vascular pathologies perivascular adipose tissue increases in volume and becomes 
dysfunctional, with altered cellular composition and molecular characteristics. PVAT 
dysfunction is characterized by its inflammatory character, oxidative stress, diminished 
production of vaso-protective adipocyte derived relaxing factors (ADRFs) and increased 
production of paracrine factors such as resistin, leptin, cytokines (IL-6, TNF-) and 
chemokines (RANTES, MCP-1). These adipocyte-derived factors initiate and orchestrate 
inflammatory cell infiltration including primarily T cells, macrophages, dendritic cells (DCs), 
B cells as well as NK cells. Protective factors such as adiponectin can reduce NADPH oxidase 
superoxide production and increase nitric oxide bioavailability in the vessel wall, while 
inflammation (e.g. IFN- or IL-17) induces vascular oxidases and eNOS dysfunction in the 
endothelium, vascular smooth muscle cells and adventitial fibroblasts. All of these events link 
dysfunctional perivascular fat to vascular dysfunction. These mechanisms are important in the 
context of a number of cardiovascular disorders including atherosclerosis, hypertension, 
diabetes and obesity. Inflammatory changes in PVAT molecular and cellular responses are 
uniquely different from classical visceral or subcutaneous adipose tissue or from adventitia, 
emphasizing unique structural and functional features of this adipose tissue compartment. 
Therefore, it is essential to develop techniques for monitoring PVAT characteristics and 
assessing its inflammation. This will lead to better understanding of the early stages of vascular 
pathologies and development of new therapeutic strategies focusing on perivascular adipose 
tissue.  
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Introduction 
Most blood vessels, apart from the vasculature in the brain are surrounded or embedded in 
perivascular adipose tissue (PVAT) (Gao, 2007). It represents around 3% of the total body 
adipose tissue mass (Siegel-Axel & Haring, 2016). While initially considered to provide 
primarily mechanistic support for the vasculature, in the recent years it became clear that PVAT 
is critical for the regulation of vascular/endothelial function in both physiology and pathology. 
In normal conditions, PVAT releases substances key for maintaining vasomotor tone and 
modulating vessel function (Galvez et al., 2006; Gao, 2007; Gollasch & Dubrovska, 2004). 
This includes beneficial adipocyte derived relaxing factor (ADRF) which has been shown to 
affect vasomotor tone and regulate important homeostatic blood vessel functions. In spite of 
vast research, the nature of this ADRF remains unidentified with adiponectin, hydrogen 
peroxide, H2S (hydrogen sulfide), prostacyclin, angiotensin 1-7 or EDHF (endothelium-
derived hyperpolarizing factor) being primary candidates (Brown et al., 2014; Szasz, Bomfim 
& Webb, 2013). Studies leading to the discovery of this novel vasorelaxant molecule have been 
initiated by a finding of Soltis and Cassis (1991), that the presence of  PVAT may decrease 
contractile responses to vasoconstrictive agents. At that time, however, endothelial nitric oxide 
(NO) and its role in the regulation of vascular function was at the central stage of vascular 
biology, thus this report was not sufficiently appreciated, until further studies showing the 
release of classical vascular relaxing factor from the PVAT (Lohn, Dubrovska, Lauterbach, 
Luft, Gollasch & Sharma, 2002). Several interesting investigations such as those of Gollasch 
(Fesus et al., 2007; Galvez et al., 2006; Gollasch & Dubrovska, 2004; Lohn, Dubrovska, 
Lauterbach, Luft, Gollasch & Sharma, 2002) and Gao (Gao, 2007; Gao, Lu, Su, Sharma & Lee, 
2007; Gao et al., 2006), provided further insights into the pharmacology and physiology of 
these mediators in the PVAT. 
The physiological importance of PVAT is emphasized further by studies showing that loss of 
adipose tissue in lipoatrophic mice (A-ZIP/F1) enhances the contractile responses of blood 
vessels, resulting ultimately in hypertension partially linked to an up-regulation of vascular 
angiotensin II type 1 receptors (Takemori et al., 2007). Moreover, the deletion of peroxisome 
proliferator-activated receptor gamma (PPAR-) in vascular smooth muscle cells (VSMCs) 
causes the loss of PVAT in the aorta (Chang et al., 2012). The interactions between PVAT and 
vascular function are tightly regulated by number of metabolic factors including AMPK (5' 
adenosine monophosphate-activated protein kinase) (Almabrouk, Ewart, Salt & Kennedy, 
2014; Almabrouk, Ugusman, Katwan, Salt & Kennedy, 2016). In pathologies associated with 
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vascular dysfunction, release of ADRF is diminished while PVAT releases number of paracrine 
factors such as adipokines (resistin, leptin, visfatin), cytokines (IL-6, TNF-), chemokines 
(regulated upon activation normal T cell expressed and secreted (RANTES, CCL5), monocyte 
chemoattractant protein 1(MCP-1, CCL2)) - all of which can directly affect vascular smooth 
muscle and endothelial cells and which initiate and orchestrate vascular inflammation. This 
imbalance between production and release of protective factors and pro-inflammatory 
molecules has been termed in similarity to endothelial dysfunction – the PVAT dysfunction 
(Guzik, Mangalat & Korbut, 2006; Guzik, Marvar, Czesnikiewicz-Guzik & Korbut, 2007). 
Such dysfunctional PVAT has been reported in a range of vascular pathologies including 
atherosclerosis, hypertension, diabetes and obesity (Guzik, Mangalat & Korbut, 2006; Ignacak, 
Kasztelnik, Sliwa, Korbut, Rajda & Guzik, 2012). While specific mechanisms and 
characteristics of PVAT dysfunction may differ, its inflammatory characteristics constitutes an 
important common denominator in a number of vascular pathologies (Figure 1), which will be 
the primary focus of the current review. Characteristics of inflammation in the PVAT is unique 
and different to mechanisms observed in typical visceral fat in obesity (Mikolajczyk et al., 
2016). This difference results not only from its direct location next to vascular wall but also 
most likely from differential release of adipokines and chemokines/cytokines. 
PVAT expands in a number of pathologies in humans. This can be systemic for example in 
obesity (Greif et al., 2009; Mahabadi et al., 2010). Local expansion of PVAT has been reported 
in relation to atherosclerotic plaque development and vascular calcifications (Lehman, 
Massaro, Schlett, O'Donnell, Hoffmann & Fox, 2010), hypertension or aortic abdominal 
aneurysm (AAA). While presence of PVAT inflammation is a common feature of vascular 
disease state its characteristic varies between different pathologies (Fig 1). 
 
Perivascular adipose tissue –brown or white? 
Adipose tissue is typically classified as white (WAT), brown (BAT) or beige according to the 
characteristic colour, but mostly in relation to mitochondrial properties and uncoupling protein 
1 (UCP-1) content. Brown adipose tissue is associated with thermogenesis, while WAT serves 
for lipid storage. WAT is less vascular and less metabolically active in comparison to BAT. 
Both BAT and WAT are under control of sympathetic nervous system, but nerve supply is 
denser in BAT than in WAT (Harms & Seale, 2013). These differences are reviewed elsewhere 
(Harms & Seale, 2013), and have been summarized in Table 1. 
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Differences in both histologic and metabolic profile are also linked to differential immuno-
inflammatory properties of these different types of adipose tissues (Galvez-Prieto et al., 2008). 
PVAT is different from other fat depots in the body through possible dynamic interplay 
between white and brown adipocytes, which result in differential functional properties (Table 
1). In rodents, PVAT surrounding thoracic aorta is mainly brown although narrow strip 
immediately adjacent to vascular adventitia is WAT. The abdominal aorta is surrounded by 
adipose tissue that is a mixture of brown and white adipocytes, whereas mesenteric arteries are 
surrounded by mesenteric fat composed mainly of white adipocytes in which these vessels are 
embedded(Brown et al., 2014; Wang, Xu, Guan, Su, Fan & Miao, 2009). In humans, PVAT 
has been attributed more histologic properties of WAT. However, its comparison to typical 
subcutaneous WAT shows clear differences. In larger vessels, which are of interest in relation 
to their propensity for atherosclerosis, PVAT commonly displays distinct morphology with 
adipocytes of a smaller size and much less differentiated phenotype than in typical WAT 
(Chang et al., 2012; Chatterjee et al., 2009; Galvez-Prieto et al., 2008), as indicated by less 
efficiency in lipid storing capacity, and lower expression levels of WAT adipocyte-specific 
genes, with some clear similarities with those in BAT. Thus, PVAT gene and protein profile is 
clearly different to WAT (Chang et al., 2012). PVAT is characterized by a less differentiated 
phenotype than classical visceral fat, closer to pre-adipocytes with particular propensity for 
release of pro-inflammatory factors and growth factors. PVAT, to greater extent than other 
adipose tissue compartments, is a conglomerate of various cell types, including adipocytes, 
preadipocytes, and mesenchymal stem cells. Pathological conditions such as angiotensin II 
(Ang II) or pro-atherosclerotic factors increase de-differentiation in PVAT adipocytes (Iwai et 
al., 2009; Tomono, Iwai, Inaba, Mogi & Horiuchi, 2008). This coincides with NF-B 
dependent increases of pro-inflammatory cytokines such as IL-6, IL-8 or chemokines such as 
MCP-1 or RANTES (Mikolajczyk et al., 2016; Skurk, Herder, Kraft, Muller-Scholze, Hauner 
& Kolb, 2005; Skurk, van Harmelen & Hauner, 2004). 
While clear evidence of the origin of perivascular adipocytes is still lacking, their origin is most 
likely distinct from other adipocytes. The fact that VSMC PPAR- is essential for generation 
of PVAT, indicates that plasticity of VSMCs is essential. This is particularly important in the 
light of the fact that vascular macrophages in atherosclerosis may be largely derived from 
VSMCs or common precursors. Common embryological origin for perivascular adipocytes and 
VSMC is therefore very likely and would explain the difference between BAT, WAT and 
PVAT (Chang et al., 2012; Omar, Chatterjee, Tang, Hui & Weintraub, 2014). 
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PVAT inflammation in vascular pathologies 
Morphological, structural and functional alterations of PVAT have been observed in the major 
vascular pathologies and in relation to cardiovascular risk factors including atherosclerosis, 
hypertension, AAA and diabetic vasculopathies (Fig 1). 
Atherosclerosis: Role of immunity and inflammation in atherosclerosis has been known for 
several decades now (Hansson & Hermansson, 2011). Studies of immune mechanisms of 
atherosclerosis have initially focused on neo-intima and atherosclerotic plaque. Recent 
evidence suggests a key role of perivascular inflammation at various stages of atherosclerosis 
(Skiba et al., 2016). Importantly, perivascular inflammation precedes atherosclerotic plaque 
and even development of endothelial dysfunction and oxidative stress in Apolipoprotein E-/- 
(Apoe-/-) mice (Skiba et al., 2016). While majority of data in atherosclerosis are focused on 
adventitial inflammation, clear links to PVAT are evident from these studies. Atherosclerotic 
mice (Apoe-/- or LDL receptor KO mice) are characterized by increased production of 
proinflammatory cytokines such as IL-6 and IL-1 in perivascular adipose tissue (Lohmann et 
al., 2009). Furthermore, perivascular inflammation is associated with marked increase of 
chemokines such as MCP-1 (CCL2) (Manka et al., 2014), MIP-1 (macrophage inflammatory 
protein 1-alpha, CCL3) (Moos et al., 2005) and RANTES (Sakamoto, Tsuruda, Hatakeyama, 
Imamura, Asada & Kitamura, 2014), which attract immune cells into injury sites. 
During the progression of atherosclerosis in Apoe-/- mice macrophages, T cells and DCs are 
recruited into perivascular adventita and adipose tissue (Galkina, Kadl, Sanders, Varughese, 
Sarembock & Ley, 2006; Moos et al., 2005) and correlated with age and lesion size (Moos et 
al., 2005). Increased number of T cells and macrophages in adventitial layer of abdominal aorta 
of Apoe-/- has been reported (Sakamoto, Tsuruda, Hatakeyama, Imamura, Asada & Kitamura, 
2014). Adventitial T and B cells are present at early stages of atherosclerosis as loose 
aggregates (Galkina, Kadl, Sanders, Varughese, Sarembock & Ley, 2006; Moos et al., 2005), 
while in late stages they can form adventitial tertiary lymphoid organs (ALTOs) (Akhavanpoor, 
Wangler, Gleissner, Korosoglou, Katus & Erbel, 2014; Hu et al., 2015). Recently, Galkina 
group have shown that smooth muscle cell-derived IL-17C plays proatherogenic role by 
supporting perivascular recruitment Th17 cells. IL-17c-/-Apoe-/- displayed reduction of aortic 
leukocytes accumulation (Butcher, Waseem & Galkina, 2016). Pro-inflammatory IL-17A-
producing T cells are present in the adventitia and blockade of IL-17A lead to reduction of 
macrophage accumulation and atherosclerosis (Smith et al., 2010). 
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While many of the above studies focus on adventitial inflammation which is best characterized 
in animal models of atherosclerosis, a close interrelationship and lack of clear anatomical 
border with PVAT makes perivascular adipose tissue essential for this process. Indeed 
transplantation of PVAT on the carotid artery increased vascular remodelling upon wire injury 
through adventitial inflammation and angiogenesis in LDL receptor knockout animals (Manka 
et al., 2014). Endovascular injury significantly upregulates pro-inflammatory MCP-1, TNF-, 
IL-6, plasminogen activator inhibitor-1 and downregulates anti-inflammatory adipokines, such 
as adiponectin, within PVAT (Takaoka et al., 2010). Immunohistochemical analyses of 
periadventitial fat revealed increased macrophages and T –cells in Apoe-/- animals compared 
with WT mice on cholesterol diet (Lohmann et al., 2009). There are more macrophages 
(CD68+ cells) in the PVAT and adventita in the LDLr-/- animals than in media and intima, in 
both atherosclerotic and non-atherosclerotic areas of the vessels (Ding, Mizeracki, Hu & 
Mehta, 2013). Consistently, Yamashita at al., (2008) showed that macrophages in the media 
and adventitia, not in the intima, are most important in expansive atherosclerotic remodelling 
via matrix degradation and smooth muscle cell reduction. In human atherosclerosis, 
perivascular macrophages near atherosclerotic lesion are polarized towards M2 phenotype 
(Stoger et al., 2012) but their role in atherosclerosis is still controversial. 
Molecular mechanisms of PVAT inflammation in atherosclerosis indicate several key targets. 
Signal transducer and activator transcription 4 (STAT4) is expressed in adipocytes and immune 
cells and may participate in PVAT inflammation. STAT4 deficiency reduces development of 
atherosclerosis and PVAT inflammation in Apoe-/- mouse (Dobrian et al., 2015) and in insulin 
resistant obese Zucker rats (Pei, Gu, Thimmalapura, Mison & Nadler, 2006). Apoe-/- animals 
show higher numbers of CD45+ cells in PVAT, but not in visceral fat, compared to Apoe-/-
STAT4-/- mouse. In particular, the number of CD8+ T cells is dramatically increased in PVAT 
of Apoe-/-mice. Reduction of PVAT inflammation was also associated with diminished 
expression of CCL5, CXCL10, CX3CL1 and TNF- in STAT4-deficient Apolipoprotein E-
deficient mice. Furthermore, STAT4 deficiency induces a bias toward anti-inflammatory 
macrophages producing IL-10 and IL-4 in PVAT of Apoe-/- mouse without affecting their total 
number (Dobrian et al., 2015). Also, tetrahydrobiopterin treatment markedly reduces leukocyte 
infiltration into atherosclerotic lesions and vascular adventitia via endothelial cell signalling 
(Schmidt et al., 2010). These studies are further supported by findings that vasoprptective 
compounds such as Mas receptor agonists prevent atherosclerosis through reduction of 
chemokines expression and accumulation on immune cells in PVAT (Skiba et al., 2016).  
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While macrophages and T cells regulate PVAT inflammation in atherosclerosis, important role 
for perivascular mast cells have recently been identified (Kennedy, Wu, Wadsworth, Lawrence 
& Maffia, 2013). During plaque progression activated mast cells accumulate in the arterial 
adventitia and promote macrophage apoptosis and microvascular leakage (Wu et al., 2015). 
Furthermore, perivascular mast cells activation promotes monocyte adhesion in CXCR2- and 
vascular cell adhesion molecule 1 (VCAM1)-dependent manner (Bot et al., 2007). 
Hypertension: Hypertension is associated with the activation of renin-angiotensin-aldosteron 
system (RAS) and increased vascular oxidative stress. Both, Ang II and ROS play crucial role 
in the initiation and maintenance of vascular inflammation. Primary site of initial inflammation 
in hypertension is within the PVAT and PVAT/adventitial border (Harrison et al., 2011; Kirabo 
et al., 2014; Mikolajczyk et al., 2016). Almost all components of the RAS, except renin, are 
expressed in the PVAT (Galvez-Prieto et al., 2008; Nguyen Dinh Cat & Touyz, 2011), which 
may play a key role in modulating perivascular inflammation in hypertension. Additionally, 
PVAT expresses a complex ROS machinery containing nicotinamide adenine dinucleotide 
phosphate oxidase (NADPH), eNOS (endothelial nitric oxide synthase) and antioxidative 
enzymes (Guzik et al., 2005; Szasz, Bomfim & Webb, 2013). PVAT-derived ROS can promote 
endothelial dysfunction, which could be achieved either by endothelial NO-scavenging by 
PVAT derived ROS or through modulation of perivascular inflammation that then affects 
endothelial function (Even, Dulak-Lis, Touyz & Dinh Cat, 2014; Ketonen, Shi, Martonen & 
Mervaala, 2010). During progression of hypertension, immune cells accumulate mainly in 
perivascular fat tissue surrounding both large and resistance vessels such as aorta and 
mesenteric arteries. It is interesting to note that while inflammation is particularly pronounced 
in PVAT, non-perivascular visceral fat immune cell infiltration is much less pronounced in 
non-obesity induced hypertension (Guzik et al., 2007; Mikolajczyk et al., 2016). 
Mice lacking T cells or monocytes exhibit blunted inflammation in response to various 
hypertensive stimuli (Guzik et al., 2007; Wenzel et al., 2011), whereas loss of lymphocyte 
adaptor protein (Lnk) gene, encoding a negative regulator of T cell activation, markedly 
enhances perivascular inflammation (Saleh et al., 2015). Moreover, pro-hypertensive stimuli 
increase tissue-homing markers on leukocytes as well as pro-inflammatory chemokines both 
of with further promote chemotaxis toward adipose tissue (Guzik et al., 2007; Hoch et al., 2009; 
Mikolajczyk et al., 2016). Accumulation of leukocytes is markedly reduced in IL-17-/-  and 
IL-6-/- Ang II-infused animals (Madhur et al., 2011). Chronic oxidative stress promotes 
vascular inflammation in hypertension. Mice lacking NADPH oxidase components such as 
p47phox, NOX1 and NOX4 are protected against hypertension (Landmesser et al., 2002; 
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Matsuno et al., 2005) while, mice with smooth muscle-targeted overexpression of p22phox 
(NADPH catalytic subunit) exhibit increased vascular superoxide production, which was 
associated with elevation of total number of leukocytes in PVAT (Wu et al., 2016) and 
increased susceptibility to vascular dysfunction. 
Aneurysms: Abdominal aortic aneurysm is an inflammatory disease associated with marked 
changes in the cellular composition of the aortic wall and PVAT. Aneurysm formation often 
coexist with atherosclerosis. Numerous inflammatory cells are involved in AAA formation 
such as neutrophils, macrophages, T and B cells as well as mast cells (Sagan et al., 2012; Spear 
et al., 2015). These immune cells are observed both within PVAT and within luminal thrombi 
and are partially linked to advanced atherosclerotic plaques (Clement et al., 2015) but they 
clearly increase susceptibility to AAA formation (Police, Thatcher, Charnigo, Daugherty & 
Cassis, 2009). Deficiency of TLR4 or myeloid differentiation factor 88 (MyD88) reduced 
perivascular inflammation and AAA formation (Owens et al., 2011). Apart from contributing 
to general inflammation, leukocytes in the PVAT may produce proteases such as cathepsins 
promoting degradation of aortic wall cells (Folkesson et al., 2016). 
In summary, PVAT inflammation is a characteristic feature of vascular pathologies. While 
there is number of similarities between perivascular inflammation in hypertension and 
atherosclerosis, there are also key differences (Fig 1). While in atherosclerosis perivascular 
immune infiltrates, relatively quickly form organized structures, forming eventually ATLOs 
(adventitial tertiary lymphoid organs), in hypertension T cell and B cell infiltration is more 
scattered. Macrophage infiltration of PVAT is more prominent in atherosclerosis than in 
hypertension. Aneurysms are so far the only pathology in humans, in which clear 
PVAT/adventitial ATLO structures have been identified. This may either be related to specific 
aneurysm pathology or may be lined to advanced atherosclerosis which typically accompanies 
AAA. 
 
How is PVAT inflammation initiated? 
Endothelial dysfunction is a key early mechanism of vascular disease. It is characterized by the 
loss of NO bioavailability accompanied by reduced production of vasoprotective substances, 
such as prostacyclin (PGI2) and increased production of vascular damaging and pathologically 
activating molecules such as ROS, endothelin, thromboxanes (Channon & Guzik, 2002). 
Importantly, the vasoprotective substances such as NO have potent anti-inflammatory 
properties, which are conveyed through inhibitory effects on adhesion molecule and chemokine 
expression. Thus, dysfunctional endothelial cells release chemokines such as RANTES, CCL2, 
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CXCL10 (Ide, Hirase, Nishimoto-Hazuku, Ikeda & Node, 2008; Mateo et al., 2006), which can 
induce leukocyte migration or activation. 
Increased ICAM1 (intracellular adhesion molecule) and VCAM1 expression, on vascular 
endothelium, is one of the hallmarks of endothelial dysfunction, linking it to inflammation. 
When such dysfunction occurs in microvessels and vasa vasorum of PVAT – it will lead to the 
development of perivascular infiltration, emphasizing a bi-directional relationship between 
vascular endothelium and PVAT. 
Oxidative stress, characterized by overproduction of superoxide anion and hydrogen peroxide 
is a key feature of endothelial dysfunction. It results in rapid scavenging of NO in blood vessel 
wall – a key mechanism of endothelial dysfunction in a number of vascular pathologies, but it 
also leads to activation of redox sensitive genes within endothelium, VSMCs and adventitia. 
Numerous pro-inflammatory genes including cytokines and chemokines as well as adhesion 
molecules are redox sensitive linking vascular oxidative stress to inflammatory processes 
(Shah, Wanchu & Bhatnagar, 2011). 
Vascular smooth muscle cells are a considerable source of chemokines and cytokines, such as 
CCL2, CCL7, CCL20, CXCL1, CX3CL1, CXCL5 and IL-6, IL-23a, IL-1 (Butcher, Waseem 
& Galkina, 2016). All of these can be essential for an induction of perivascular inflammation. 
Increased expression of key chemokines in the vascular wall is observed at early stages of 
atherosclerosis or hypertension. Chemokines receptors, such as CCR2, CCR5 and CXCR4 are 
also upregulated by oxygen radicals (Chan et al., 2012; Zhang, Chen, Song, Chen & Rovin, 
2005). Thus, endothelial dysfunction and vascular oxidative stress may initiate and exacerbate 
PVAT inflammation evoked by key risk factors for atherosclerosis and chemokines are key 
mediators of this process. 
 
Chemokines in PVAT inflammation 
Role of chemokines in initiating and orchestrating inflammation and specific immune 
responses is widely recognised (Henrichot et al., 2005). These small molecular weight 
molecules (7-12 kDa) can be divided into 4 subclasses, C, CC, CXC and CX3C chemokines 
based on the position of N-termal cysteine (van der Vorst, Doring & Weber, 2015). 
Chemokines and their receptors are widely expressed on vascular cells and on leukocytes and 
play a key role in the recruitment immune cells to the sites of inflammation or injury in response 
to chemokine gradient in many cardiovascular diseases. Conditioned media from PVAT 
induces a chemotaxis of monocytes and T cells (Chatterjee et al., 2013; Miao & Li, 2012; 
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Mikolajczyk et al., 2016). Role of CCL2, CCL5 and CX3CL1 in the recruitment of circulating 
monocytes and T cells in atherosclerosis is well established (Charo & Taubman, 2004; van der 
Vorst, Doring & Weber, 2015). CCL2 produced by adipocytes has been identified as a potential 
factor contributing to macrophage infiltration into adipose tissue (Chan et al., 2012; Kanda et 
al., 2006). RANTES chemokine, in turn, can be produced by T cells, macrophages, VSMC, 
endothelial cells as well as PVAT adipocytes (Krensky & Ahn, 2007; Mateo et al., 2006; Surmi 
& Hasty, 2010) and is key in recruitment of leukocytes into inflammatory or infection sites 
(Marques, Guabiraba, Russo & Teixeira, 2013). RANTES chemokine is increased in PVAT in 
hypertension (Guzik et al., 2007) and is characteristic for early stages of atherosclerosis 
(Podolec et al., 2016; Veillard et al., 2004). RANTES chemokine receptors (CCR1, CCR3 and 
CCR5) are elevated in vascular diseases in clear relation to PVAT inflammation (de Jager et 
al., 2012; Guzik et al., 2007; Marques, Guabiraba, Russo & Teixeira, 2013; Mikolajczyk et al., 
2016). Recently, we have demonstrated that RANTES-/- reduces angiotensin II-induced 
accumulation of T cells, macrophages and DCs in the PVAT (Mikolajczyk et al., 2016). 
Genetic deletion or blockade of chemokine RANTES, using the peptide antagonist Met-
RANTES, inhibits leukocyte infiltration to the site of inflammation (Marques, Guabiraba, 
Russo & Teixeira, 2013) and is effective in modulating perivascular and plaque inflammation 
in hypertension (Mikolajczyk et al., 2016) and atherosclerosis (Veillard et al., 2004). 
CXCL10 (IP-10) is a IFN- inducible protein produced by T cells, NK and NKT cells, 
monocytes, DCs but also by fibroblasts and endothelial cells (Bondar, Araya, Guzman, Rua, 
Chopita & Chirdo, 2014). It is particularly important in chronic inflammation, including 
atherosclerosis and hypertension (Ide, Hirase, Nishimoto-Hazuku, Ikeda & Node, 2008). 
Circulating levels of CXCL10 are increased in hypertension (Antonelli et al., 2008) and 
coronary heart disease (Safa et al., 2016). CXCL10 exerts its biological effects mainly via 
binding to CXCR3. The CXCL10/CXCR3 axis is important in regulating T cell responses in 
atherosclerosis. Deficiency of CXCR3 or using CXCR3 antagonist reduces lesion formation in 
Apoe-/- animals, reduce T cell migration and upregulates anti-inflammatory molecules (van 
Wanrooij et al., 2008; Veillard et al., 2005). Expression of CXCL10 is reduced in the PVAT 
of STAT4-/-Apoe-/- mice which, are protected from PVAT inflammation (Dobrian et al., 
2015). Expression of CXCL10 correlates with STAT1 phosphorylation in vascular cells in 
plaques from human carotid arteries (Chmielewski et al., 2014) and STAT1 and NF-B both 
regulate CXCL10 (Veillard et al., 2005). CXCL10 has direct effects on vascular wall cells as 
it induces migration and proliferation of endothelial cells and VSMC. Ide et al. demonstrated 
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that IP-10 increases the expression of RAS components in endothelial cells (Ide, Hirase, 
Nishimoto-Hazuku, Ikeda & Node, 2008), making it almost a prototypical “bi-directional” 
cytokine in vascular biology, through which vessel wall can regulate inflammation and 
inflammatory cells that can produce CXCL10 affect vascular wall biology. 
 
Immune cells in PVAT inflammation  
PVAT inflammation in vascular pathologies appears to differ from typical visceral AT 
inflammation in obesity. 
In diseases such as hypertension, hypercholesterolemia or diabetes PVAT inflammation may 
occur in the absence of obesity or metabolic syndrome. This may be related to vicinity of blood 
vessel wall, which affects development of vascular inflammation and in relation to the presence 
of vasa-vasorum enabling greater metabolic activity and a clear route for immune cells to 
migrate into PVAT. There are numerous differences in cellular and humoral characteristics of 
PVAT inflammation when compared to well described inflammation within classical visceral 
adipose tissue depots. This is manifested by unique cellular composition and inflammatory 
cytokine signature (Skiba et al., 2016).  
T cells: PVAT T-cell infiltration may precede and exceed macrophage infiltration in animal 
models and in humans with hypertension and hypercholesterolemia. This is in contrast to 
typical visceral fat where macrophage dependent inflammation predominates from the earliest 
stages of disease (Wu et al., 2007). Perivascular T cells represent morphologically and 
functionally heterogeneous cellular compartment. Both T helper cells (CD4+) and CD8+ 
cytotoxic cells are present in the PVAT with a high proportion of CD3+CD4-CD8- T cells, 
which are predominantly  T cells (Guzik et al., 2007; Mikolajczyk et al., 2016). Recent 
studies of PVAT T cells indicate their effector and memory functions (Itani et al., 2016). These 
include primarily TH1 and TH17 cells (producing IFN- and TNF- or IL-17, respectively) or 
in some stages of pathology-TH2 cells. CD8+ lymphocytes infiltrated PVAT may also 
functionally differ depending on their content of granzyme B/perforin or IFN-/TNF- 
(Broere, Apasov, Sitkovsky & van Eden, 2011). Ang II and hypertension increase the 
percentage of circulating T cells with effector phenotype which next accumulate in PVAT 
trigger inflammation and promote vascular dysfunction (Guzik et al., 2007; Mikolajczyk et al., 
2016). PVAT T cells express CD69, CD25 and CD44 markers which may confer activation as 
well as tissue phenotype and they commonly express high levels of receptors for inflammatory 
chemokines (CCR1, CCR5,CCR3) (Vinh et al., 2010). and adhesion molecules (CD44) which 
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are key to their recruitment to PVAT (Guzik et al., 2007; Mikolajczyk et al., 2016). Substantial 
proportion of PVAT CD4+ and CD8+ T cells expressed CD25 activation marker and produce 
IFN- and TNF-. Ang II induce a shift of T cells toward TH1 producing IFN-, which is 
dependent on T cell AT1 receptor (Shao et al., 2003). T regulatory cells (Treg) represent a small 
but functionally significant population of T cells in the PVAT. They are characterized by high 
CD25 and presence of the forkhead transcription factor (FOXP3) and through release of 
suppressive anti-inflammatory cytokines (IL-10, TGF-) has critical roles in immune 
homeostasis and preventing excessive immune responses (Sakaguchi, Miyara, Costantino & 
Hafler, 2010). Interestingly, adoptive transfer of Tregs ameliorates vascular dysfunction, reduces 
blood pressure and infiltration of immune cells in blood vessels and perivascular tissue in Ang 
II-treated mice (Matrougui et al., 2011). Treg also prevent monocyte/macrophage and T 
lymphocyte PVAT infiltration associated with various vascular insults such as wire injury, 
atherosclerosis and Ang II or aldosterone (Kasal et al., 2012). Finally, a subset of CD8+ 
regulatory, cells that were also found in the PVAT, may mediate cell death through 
perforin/granzyme-dependent pathways (Grossman, Verbsky, Barchet, Colonna, Atkinson & 
Ley, 2004), controlling immune responses but also affecting apoptosis and function of adjacent 
vascular cells. While other subpopulations of T cells such as invariant NK T cells etc have been 
reported in PVAT their functional importance is not clear.  
B cells: In atherosclerosis B cells are primarily localized within the plaque and ATLOs (Sage 
& Mallat, 2014). Little is known about B cell characteristics and function in the PVAT. This 
is interesting because, recent studies show that B cells constitute up to 20% of PVAT 
leukocytes where they interact with T cells (Parker, 1993; Wei, Spizzo, Diep, Drummond, 
Widdop & Vinh, 2014), but are also scattered independently of other immune cells. Chan et al 
found that Ang II-induced hypertension was associated with increase of activated of B cells in 
the PVAT. Moreover, this was associated with elevation of serum and aortic antibody 
deposition of IgG2b and IgG3. Depletion of B cells protected against hypertension (Chan et 
al., 2015). B regulatory cells have also been described in atherogenesis (Strom et al., 2015), 
thus better understanding of the links between pro- and anti-inflammatory B cells in PVAT is 
needed. The links between well characterized role of adventitial and ATLO B cells in 
atherosclerosis, to their PVAT infiltration need to be better understood. 
Macrophages: Macrophages typically represent about 10-15% of stromal-vascular fraction, 
while their number increases to 45-50% during obesity (Wynn, Chawla & Pollard, 2013). 
Macrophage infiltration in adipose tissue has been first described in a form of crown structures 
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in obesity, it has been linked to the expression of chemokines and adhesion molecules in the 
fat (Cancello et al., 2005; Kolak et al., 2007). Macrophages accumulate in PVAT and adventitia 
during hypercholesterolemia and hypertension, also in the absence of obesity (Chan et al., 
2012; Moore et al., 2015) and release free radicals via NOX2 NADPH oxidase (Kotsias, 
Hoffmann, Amigorena & Savina, 2013). Infiltrating macrophages produce cytokines such as 
IL-6, IFN-, TNF-, that change vascular and PVAT cell biology. While M1 macrophages, 
were classically defined in obesity and atherosclerosis, recent studies point to significant M2 
macrophage infiltration in PVAT, which may regulate PVAT adipokine release, as well as 
perivascular fibrosis. Classically M1 macrophages produce IL-12 and IL-23 and promote TH1 
and TH17 cells (Wynn, Chawla & Pollard, 2013), while M2 produce IL-10 and participate in 
TH2 type and pro-fibrotic responses (Murray & Wynn, 2011). PVAT macrophages are also 
important in the regulation of T cells activation through antigen presentation, expression 
costimulatory ligands and release of mediators that modulate their function and/or chemotaxis 
(Shirai, Hilhorst, Harrison, Goronzy & Weyand, 2015). T cell dependent responses may 
reciprocally regulate PVAT macrophage infiltration. For example, loss of Lnk gene, which 
increased T cell activation, enhances macrophage (F4/80+ cells) infiltration into PVAT, and 
Ang II infusion enhances this effect (Saleh et al., 2015). 
Dendritic cells: DCs are key in regulating adaptive immune responses in cardiovascular 
diseases. They are located primarily on the adventitia-PVAT border but have been reported in 
PVAT (Mikolajczyk et al., 2016; Wei, Spizzo, Diep, Drummond, Widdop & Vinh, 2014). This 
has been identified in hypertension and is enhanced by chronic oxidative stress leading to 
formation of immunogenic isoketal-protein adducts, which can accumulate in DCs and 
promote T cells activation (Kirabo et al., 2014; Wu et al., 2016). Dendritic cells release 
mediators such as IL-1, IL-6 and IL-23 which polarize T cells to produce IL-17A as well as 
TNF- and IFN- which has been implicated in hypertension and PVAT inflammation (Guzik 
et al., 2007; Marko et al., 2012) (Fig 2). Moreover, blocking of CD28/CD80/CD86 co-
stimulation axis between DC and T cells prevent PVAT inflammation (Vinh et al., 2010). 
However, the role of DCs either in PVAT or adventitia still raises more questions and answers 
especially in relation to their migratory capacity into secondary lymphoid organs and in relation 
to understanding the possible antigens/neo-antigens they would be presenting to activate T 
cells (Kirabo et al., 2014) (Fig 2). 
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NK cells: Natural Killer cells have been identified in PVAT although their role is much less 
clearly defined than in visceral adipose tissue where they link obesity-induced adipose stress 
to inflammation and insulin resistance in part through IFN- release (Wensveen et al., 2015). 
Adventitial Tertiary Lymphoid Organs (ATLOs): Antigen presenting cell (APC)- T cell 
interactions occur primarily in secondary lymphoid organs such as lymph nodes and the spleen 
(Junt, Scandella & Ludewig, 2008). Such interactions have however been demonstrated in 
vascular adventitia (Koltsova et al., 2012) and possibly PVAT (A. Vinh, personal 
communication) in the context of chronic vascular inflammation, in atherosclerosis or 
hypertension (Fig 1). Such interactions could trigger development of and be sustained by 
tertiary lymphoid organs (TLOs) (Hansson & Hermansson, 2011). TLOs are organized 
aggregates of immune cells formed in post embryonic life (GeurtsvanKessel et al., 2009). They 
can be found around blood vessels in chronic allograft rejection, atherosclerosis, pulmonary 
hypertension, and in patients with chronic obstructive pulmonary disease (Neyt, Perros, 
GeurtsvanKessel, Hammad & Lambrecht, 2012; Perros et al., 2012; Yadava, Bollyky & 
Lawson, 2016). Interestingly, TLO formation is reversible when inflammation is resolved or 
after therapeutic intervention (Drayton, Liao, Mounzer & Ruddle, 2006). 
Development of TLOs is orchestrated by various chemokines and cytokines such as CXCL12, 
CXCL13, CCL19, CCL20, CCL21, lymphotoxin- and lymphotoxin- (Akhavanpoor, 
Wangler, Gleissner, Korosoglou, Katus & Erbel, 2014; Rangel-Moreno et al., 2011). 
Interestingly, also IL-17 contributes to the formation of TLOs (Rangel-Moreno et al., 2011). 
Immune cells can be organized in follicle-like structures called ALTOs. They can be found  in 
murine models of atherosclerosis and AAA (Hu et al., 2015; Spear et al., 2015). Recently, Hu 
et al. in very elegant study showed that aging immune system employs ALTOs to control 
atherosclerosis related T cell immunity. VSMC- lymphotoxin  receptors (LTRs) maintain 
ALTO structure and attenuate atherosclerosis (Hu et al., 2015). These structures are evident in 
human aorta in the context of aortic abdominal aneurysms (Clement et al., 2015). 
Origins of PVAT immune cells  
While substantial number of immune cells during perivascular inflammation are recruited by 
chemotaxis (Henrichot et al., 2005), some immune cells in the vascular wall are chronically 
resident within the vessel wall. This includes primarily resident macrophages (Ensan et al., 
2016; Robbins et al., 2013), which can proliferate in atherosclerotic plaque and potentially in 
PVAT, as well as resident memory T cells (Schenkel, Fraser, Beura, Pauken, Vezys & 
Masopust, 2014). Resident macrophages are important as they drive the influx of subsequent 
 16 
inflammatory leukocytes such as monocytes, neutrophils and T cells (Asano et al., 2015). The 
propensity for such recruitment based on peripheral blood subpopulations of either monocytes 
or T cells remains disputable (Weber et al., 2016). Using multiple fate-mapping approaches, it 
has recently been shown that arterial macrophages arise embryonically from CX3CR1(+) 
precursors and postnatally from bone marrow-derived monocytes that colonize the tissue 
immediately after birth (Ensan et al., 2016). Survival of resident arterial macrophages depends 
on chemokines, in particular on fractalkine (CX3CL1) axis, expression of which is critical in 
human atherosclerosis and vascular disease (Lucas, Bursill, Guzik, Sadowski, Channon & 
Greaves, 2003). 
Similarly to myelo-monocytic cell lineage, PVAT T cells are either acutely recruited during 
the development of pathology or may have tissue-resident memory T cell (TRM cells) 
characteristics, identified on the basis of phenotypic markers CD69 and CD103 (Clark, 2015; 
Mackay et al., 2013). TRM cells express low level of receptors such as CCR7 (Bromley, Thomas 
& Luster, 2005; Clark, 2015) and sphingosine-1-phosphate receptor 1 (Resop, Douaisi, Craft, 
Jachimowski, Blom & Uittenbogaart, 2016) which promote exit cells from the tissues. TRM 
cells express high levels of CD44 and low levels of CD62L and release number of effector 
cytokines such as IFN- or TNF- (Slifka & Whitton, 2000). Subset of TRM cells mediate the 
protective immunity, however, dysregulation of TRM can contribute to autoimmune and 
inflammatory diseases. While potential role of TRM in vascular pathologies is of great interest, 
other lymphocytes, including classical effector T cells, natural killer T cells, NK cells and Treg 
cells have been described in PVAT. Most of these are likely acutely recruited into PVAT. 
T cell recruitment to PVAT may be controlled by sympathetic nervous system nerve endings 
in PVAT and adventitia (Guzik & Mikolajczyk, 2014; Itani et al., 2016; Marvar et al., 2010). 
Recent evidence suggests central role for T cells of splenic origin in the initiation of 
inflammation in hypertension (Carnevale et al., 2014; 2016). These studies from Lembo and 
Carnevale’s group show elegantly that hypertensive challenges activate splenic sympathetic 
nerve discharge to prime immune response and stimulate immune cell egression from the 
spleen into target organs, including PVAT (Carnevale et al., 2014; 2016). 
The characteristics of PVAT dendritic cells may be divergent. This is particularly important in 
the light of recent discoveries that plasmacytoid DCs play a key role in atherosclerosis and 
infiltrate atherosclerotic plaques (Sage et al., 2014). Their role in the PVAT remains unclear. 
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Mechanisms linking PVAT inflammation to vascular dysfunction.  
Conditioned media from dysfunctional PVAT in models of vascular disease, induces VSMC 
proliferation and endothelial dysfunction (Chatterjee et al., 2013; Miao & Li, 2012; 
Mikolajczyk et al., 2016). This is in part mediated by adipokines, which has been reviewed 
elsewhere (Mattu & Randeva, 2013; Tilg & Moschen, 2006), but may also be dependent on 
cytokines released by activated inflammatory cells in the PVAT. Most evidence, point to the 
key role of IFN-, IL-17, IL-6 and TNF- in regulating this process (Matusik, Guzik, Weber 
& Guzik, 2012) (Fig 2). 
Pro-inflammatory cytokines and endothelial function: IFN is one of the key cytokines 
produced by T cells, NK cells as well as some vascular cells. IFN- classical function is in the 
activation of monocytes/macrophages along with polarisation of immune cells into pro-
inflammatory phenotype (Knorr, Munzel & Wenzel, 2014). Importantly, acting on endothelial 
cells, IFN- impairs endothelium-dependent relaxation as demonstrated in ex vivo studies 
(Mikolajczyk et al., 2016) as well as in vivo using IFN- knockout mice (Kossmann et al., 
2013). Furthermore, reduced recruitment of IFN- producing cells into PVAT in RANTES-/- 
hypertensive animals protects them from impaired endothelium-dependent relaxation, while 
having no effect on endothelium-independent relaxation (Mikolajczyk et al., 2016). 
Interleukin-6 which is produced by macrophages, T cells, DC as well as PVAT adipocytes can 
directly affect endothelial cells (Pietrowski, Bender, Huppert, White, Luhmann & Kuhlmann, 
2011). It mediates increase of superoxide production and endothelial dysfunction by affecting 
NO-cGMP signalling pathway (Orshal & Khalil, 2004; Schramm, Matusik, Osmenda & Guzik, 
2012). IL-6 deficiency prevents vascular dysfunction in spite of various damaging stimuli 
(Schrader, Kinzenbaw, Johnson, Faraci & Didion, 2007). Treatment of C57BL/6J animals in 
vivo or ex vivo incubation blood vessels with IL-6 impairs endothelium-dependent relaxation 
(Wassmann et al., 2004). IL-6 is also necessary for TH17 cells differentiation (Bettelli et al., 
2006), another T cell subpopulation with strong pro-inflammatory impact on endothelial and 
vascular smooth muscle cells. IL-17 is a potent activator of the endothelial cells promoting 
expression of adhesion molecules (Roussel et al., 2010). IL-17A activates RhoA/Rho-kinase 
and increases inhibitory eNOS Thr495 phosphorylation in endothelial cells leading to 
decreased NO production (Nguyen, Chiasson, Chatterjee, Kopriva, Young & Mitchell, 2013). 
IL-17A, IFN- as well as IL-6 synergize their effects with TNF- to modulate inflammatory 
responses (Ruddy et al., 2004). TNF- is produced by a wide range of cells types including 
immune cells, vascular cells and adipocytes (Mendizabal, Llorens & Nava, 2013). Stimulation 
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of endothelial cells with this pro-inflammatory cytokine decrease eNOS expression (Hot, 
Lenief & Miossec, 2012) by destabilization of eNOS mRNA (Neumann, Gertzberg & Johnson, 
2004). TNF-, through NF-B, enhances ROS production by endothelial NADPH oxidases. 
In hypertension, Ang II infusion stimulates T cells to produce TNF- and etanercept (TNF- 
antagonist) blunts vascular superoxide production (Guzik et al., 2007). Moreover, TNF- 
increases expression of endothelial adhesion molecules and production of pro-inflammatory 
chemokines such as CCL5, CCL7, CCL8 or CXCL9 (Hot, Lenief & Miossec, 2012). Combined 
treatment with TNF- and IL-17 promotes synergistic activation of endothelial cells to express 
adhesion molecules and chemokines that enhance immune cells migration (Griffin et al., 2012). 
Contrary action is performed by IL-10, produced by T regulatory cells, selected macrophages 
and DCs (Krause et al., 2015; Saraiva & O'Garra, 2010). This anti-inflammatory cytokine 
reduces NADPH-dependent oxidative stress and increases production of NO by enhancing 
phosphorylation and activation of eNOS (Kassan, Galan, Partyka, Trebak & Matrougui, 2011). 
IL-10 inhibits activation of p38 MAPK (mitogen-activated protein kinase), which contributes 
to stimulation of pro-inflammatory cytokines but can also regulate NADPH oxidases (Konior, 
Schramm, Czesnikiewicz-Guzik & Guzik, 2014; Kontoyiannis et al., 2001). 
Effects of cytokines produced by immune cells on VSMCs: Inflammatory cytokines released in 
PVAT modulate smooth muscle cell constriction, proliferation and migration (McMaster, 
Kirabo, Madhur & Harrison, 2015). Similarly to its effects in endothelial cells, IL-6 
significantly increases Ang II-mediated ROS production in VSMCs (Wassmann et al., 2004). 
In vivo treatment of C57BL6 animals with IL-6 increases vascular AT1 receptors and mediates 
medial hypertrophy (Schrader, Kinzenbaw, Johnson, Faraci & Didion, 2007). It also enhances 
constriction of the blood vessels (Orshal & Khalil, 2004). Further, IL-6 has been reported to 
play role in VSMC migration and proliferation (Chava et al., 2009). IL-17 receptors are also 
present on VSMCs (Jin & Dong, 2013). IL-17A induces expression of mRNA for collagens I, 
III and V in a p38MAP kinase dependent fashion leading to collagen deposition and loss of 
aortic compliance (Wu et al., 2014). Blood vessels from Ang II-treated IL-17A-/- mice are 
protected from vascular dysfunction with dramatically blunted superoxide production and 
fibrosis (Madhur et al., 2010). This is because, IL-17A induces NADPH-oxidases to produce 
superoxide anion, hydrogen peroxide and therefore can regulate redox sensitive pro-
inflammatory cytokines (IL-6, MCP-1, granulocyte-colony stimulating factor, granulocyte-
macrophage colony-stimulating factor) (Pietrowski, Bender, Huppert, White, Luhmann & 
Kuhlmann, 2011). Synergistically with TNF-, IL-17A increases the expression of CCL8, 
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CSF3 (colony stimulating factor 3), CXCL2 and CCL7 in human aortic smooth muscle cells 
(Madhur et al., 2010). 
Interferon- can also act directly on VSMC to induce proliferation (Wang et al., 2007) or 
apoptosis (Rosner et al., 2006). Neutralization of IFN- prevents outward vascular remodelling 
of human coronary arteries induced by allogenic T cells in SCID/beige mice (Wang et al., 
2004). IFN- induces ICAM1 mRNA expression in smooth muscle cells (Chung et al., 2002). 
IFN- has also strong impact on superoxide production by upregulation expression and activity 
of NOXs in human aortic smooth muscle cells (Manea, Todirita, Raicu & Manea, 2014). 
Effects of cytokines produced by immune cells on perivascular adipocytes: As discussed above, 
part of the effects, through which inflammation mediates vascular function is dependent on 
regulation of classical adipokine expression and release. Adiponectin has a wide range of anti-
inflammatory effects whereas leptin has a pro-inflammatory effects (Tilg & Moschen, 2006). 
Both are also critical in regulating vascular function making them prototypical bi-directional 
adipokines in vascular biology (Antonopoulos et al., 2015; 2016; Woodward, Akoumianakis 
& Antoniades, 2016) including potent NO-releasing vasorelaxant properties (Cheng et al., 
2007). Production of adiponectin can be inhibited by pro-inflammatory cytokines such as TNF-
, IL-6 and IL-17A (Fasshauer et al., 2003; Maeda et al., 2002; Noh, 2012). Leptin is produced 
mainly by adipocytes and has structural similarity to IL-6, IL-12, IL-15. IL-17A and TNF- 
increase leptin production (La Cava & Matarese, 2004; Noh, 2012). Leptin apart from direct 
effects on endothelial NO production and VSMCs can affect leukocyte chemotaxis, release of 
oxygen radicals, VSMC proliferation and expression of adhesion molecules on endothelial and 
vascular smooth muscle cells (La Cava & Matarese, 2004). While adiponectin and leptin have 
been well investigated, PVAT shows particularly high expression of resistin, which also exerts 
pro-inflammatory effects. Resistin upregulates the expression of VCAM1 and ICAM and/or 
induction of CCL2 as well as endothelin-1 from endothelial cells (Bokarewa, Nagaev, 
Dahlberg, Smith & Tarkowski, 2005) and can induce endothelial dysfunction. Gene expression 
of resistin is induced by pro-inflammatory cytokines including IL-1, IL-6 and TNF- (Kaser, 
Kaser, Sandhofer, Ebenbichler, Tilg & Patsch, 2003). Finally, dysfunctional adipocytes in 
PVAT can produce high levels of classical chemokines MCP-1, IL-8 and IL-6 further 
contributing to PVAT inflammation.  
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Conclusions  
Dual role of PVAT in the regulation of vascular function is closely linked with PVAT as a site 
of development of vascular inflammation. Protective role of PVAT in physiological conditions 
linked to ADRF release has been demonstrated by numerous studies including seminal studies 
showing increased vascular dysfunction and hypertension in lipoathrophic mice. This led to 
conclusion that “fat is not always bad”. Soon however, in parallel to endothelial dysfunction, 
a concept of dysfunctional PVAT has been developed, characterized by loss of PVAT 
protective properties. This has been linked initially to changes in adipokine profile, but it soon 
became apparent that PVAT dysfunction is orchestrated by inflammatory responses. In such 
conditions, perivascular adipocytes de-differentiate, and are no longer primarily lipid storing 
cells but become a metabolically active synthetic tissue, that produces pro-inflammatory 
cytokines and chemokines and precipitates the key role of inflammation in cardiovascular 
disease (Fig 3). This occurs in number of pathologies including hypertension, early 
atherosclerosis, hypercholesterolemia or diabetes. Importantly loss of perilipin, which directly 
induces such change in PVAT phenotype results in development of spontaneous hypertension 
and vascular dysfunction with striking PVAT adipocyte de-differentiation and inflammatory 
cell infiltration (Zou et al., 2016). These studies show, that PVAT plays a mechanistic role in 
the development of vascular dysfunction, closing a vicious circle of vascular disease 
pathogenesis. It still remains unclear how dysfunctional, inflamed PVAT affects vascular 
dysfunction, remodelling and disease. Is it just an entry point for adventitial inflammation, or 
is it itself a source of cytokines and chemokines which affect intimal and medial layers of the 
vessel as well? Whatever the exact mechanism will be – PVAT inflammation appears to be a 
tightly regulated process, early in the vascular disease pathogenesis, that can constitute a 
valuable target for future therapies.  
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These Tables of Links list key protein targets and ligands in this article that are hyperlinked* 
to corresponding entries in http://www.guidetopharmacology.org, the common portal for 
data from the IUPHAR/BPS Guide to PHARMACOLOGY (Southan et al., 2016), and are 
permanently archived in The Concise Guide to PHARMACOLOGY 2015/16 (a,b,c,d,eAlexander et 
al., 2015a,b,c,d,e). 
 
Abbrevations 
AAA - aortic abdominal aneurysm  
ADRF - adipocyte derived relaxing factor 
Ang II - angiotensin II 
Apoe - Apolipoprotein E 
ATLO - adventitial tertiary lymphoid organ 
BAT - brown adipose tissue  
CCL - chemokine (C-C motif) ligand 
CD - cluster of differentiation 
CX3CL - chemokine (C-X3-C motif) ligand 
CXCL - chemokine (C-X-C motif) ligand 
CXCR - CXC chemokine receptor 
EDRF – endothelium-derived relaxing factor  
eNOS - endothelial nitric oxide synthase 
MCP-1 - monocyte chemoattractant protein 1, CCL2 
NADPH - nicotinamide adenine dinucleotide phosphate-oxidase 
PVAT - perivascular adipose tissue  
TARGETS   
Other protein 
targetsa 
CD44 
TNF-α CD69 
CD3 CXCR3 
GPCRsb Enzymese 
Angiotensin 1-7  APMK 
CCR2  eNOS 
CCR3 Nuclear hormone 
receptorsc 
CCR4  PPARγ 
LIGANDS CXCL3 
Adiponectin CXCL5 
Ang II  IFN- 
CCL12 IL-10 
CCL2 IL-17A 
CCL20 IL-17C 
CCL5 IL-1 
CCL7 IL-23 
CCL8 IL-6 
CXCL1 Leptin 
CXCL10 PGI2 
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RANTES - regulated upon activation, normal T cell expressed and secreted, CCL5 
STAT - Signal transducer and activator transcription  
TH17 - IL-17 producing T cells  
Treg - T regulatory lymphocytes 
TRM - tissue-resident memory T cell 
VCAM1 - vascular cell adhesion molecule 1 
VSMCs - vascular smooth muscle cells 
WAT - white adipose tissue  
TLO - tertiary lymphoid organs 
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Figure 1. Central role of perivascular adipose tissue inflammation in the regulation of 
vascular disease. Differential role of PVAT and vascular compartments in physiological 
state and in the development of vascular pathology in hypertension and atherosclerosis.  
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Figure 2. Cellular and humoral components of PVAT inflammation and their 
interactions in the regulation of vascular homeostasis and vascular dysfunction. Detailed 
description is provided within the text.  
 
 
Figure 3. Balancing anti- vs. pro-inflammatory properties and functions of perivascular 
adipose tissue.  
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Table 1. Key differences between white, brown and perivascular adipose tissue  
 
 WAT BAT PVAT References 
Location 
Subcutaneous and 
visceral 
Suprarenal, 
interscapular, 
neck region in 
human infants 
Surrounds blood 
vessels 
(Brown et al., 
2014) 
Morphology 
Large 
adipocytes 
Small 
adipocytes 
Small adipocytes 
Cedikova et al. 
(2016); 
(Chatterjee et al., 
2009) 
Lipid droplet Single, large Multiple, small Multiple, small 
(Brown et al., 
2014); Cedikova 
et al. (2016); 
(Chang et al., 
2012) 
Origin/development 
Pdgfr-  
progenitors 
Myf5+  
progenitors 
SM22+ 
progenitors 
Brown et al. 
(2014); Harms 
and Seale (2013) 
Major function 
Energy 
storage 
Heat  
production 
Vascular 
regulation, 
heat production 
(Chang et al., 
2012; Harms & 
Seale, 2013) 
Mitochondria/UCP1 
+/+ (nearly 
undetectable) 
+++/+++ ++(+)/++(+) 
Cedikova et al. 
(2016) 
Adipocyte specific 
genes 
PPAR, PLIN1, 
HOXC8, TCF21, TLE3, 
C/EBP, Rb, RIP140, 
APOL7C, DAPL1, 
NANT, SNCG, STAP1, 
GRAP2, MEST 
ZIC1, LHX8, 
EVA1, PDK4, 
EPSTI1, PRDM16, 
CIDEA, ELOVL3, 
SCL27A2, 
COX7A1, CPT1B, 
KNG2m ACOT11, 
DIO2, BMP7 
Similar to BAT 
Cedikova et al. 
(2016); 
Fitzgibbons, 
Kogan, Aouadi, 
Hendricks, 
Straubhaar and 
Czech (2011); 
Harms and Seale 
(2013) 
 
 
